Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer

Wenbo Yang, Hongze Chen, Guanqun Li, Tao Zhang, Yuhang Sui, Liwei Liu, Jisheng Hu, Gang Wang, Hua Chen, Yongwei Wang, Xina Li, Hongtao Tan, Rui Kong, Bei Sun, Le LiJournal of Translational Medicine 2023 · DOI

TL;DR

This study identifies Caprin-1 as a key driver of pancreatic cancer (PDAC) progression, demonstrating its role in activating autophagy and modulating the tumor immune microenvironment. Targeting Caprin-1 could offer a novel therapeutic strategy for this aggressive cancer.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is notoriously aggressive, characterized by rapid progression and poor patient outcomes, often due to late diagnosis and resistance to current therapies like chemotherapy and immunotherapy. A critical challenge in treating PDAC is understanding the complex interplay between tumor genetics, its microenvironment, and immune evasion. While autophagy has been implicated in cancer, its precise role in PDAC and how it interacts with the immune system remains an area needing deeper investigation. This paper aims to unravel the genetic mechanisms driving PDAC progression, focusing on how specific genes influence tumor growth and immune modulation, with the ultimate goal of identifying new therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Genomic Analysis: They utilized bulk RNA sequencing and spatial transcriptome sequencing to identify gene signatures associated with advanced PDAC and poor prognosis. This involved comparing gene expression profiles between early and advanced stage tumors, as well as between patients with short-term versus long-term survival. Ingenuity Pathway Analysis (IPA) and Gene Ontology (GO) analysis were used to predict biological processes.
  • In Vitro and In Vivo Experiments:
    • Cell Lines: Standard pancreatic cancer cell lines (Bxpc-3, Panc-1, CFPAC, SW1990) were used to study the effects of Caprin-1 overexpression and knockdown on cell proliferation and colony formation.
  • Animal Models: Patient-derived xenograft (PDx) and orthotopic mouse models were established to investigate Caprin-1's role in tumor growth and progression in vivo.
  • Autophagy Assays: Techniques like mRFP-GFP-LC3 assay were used to track autophagy flux.
  • Protein Interaction Studies: Co-immunoprecipitation (Co-IP) assays and mass spectrometry were employed to identify proteins that interact with Caprin-1, specifically focusing on autophagy-related proteins like ULK1 and STK38.
  • Human Specimen Analysis: Immunohistochemistry (IHC) was used to assess Caprin-1 expression in human PDAC tissues and correlate it with clinical parameters and patient survival. Serum samples were also analyzed.

Datasets

  • GEO Database: Data from GEO database (GSE62165 and GSE84219) were used for initial identification of differential gene expression between tumor stages and survival groups.
  • Human PDAC Samples: A cohort of 122 PDAC samples (fixed and embedded in paraffin for tissue microarrays) and 74 fresh PDAC tissues were collected for IHC, RNA sequencing, and other analyses. Serum samples from healthy controls and PDAC patients were also utilized.
  • TCGA Database: Used for validating the association between Caprin-1 expression and patient prognosis.

Key Insights and Ideas

  • Caprin-1 as a PDAC Driver: The study strongly implicates Caprin-1 as a key oncogene in PDAC, showing its upregulation in advanced tumors and its correlation with poor patient survival.
  • Autophagy Activation: Caprin-1 directly promotes autophagy activation by interacting with and modulating the phosphorylation of ULK1, a critical initiator of autophagy. This autophagy activation appears to be a pro-tumorigenic mechanism.
  • Immune Modulation: Caprin-1 influences the tumor microenvironment by recruiting CD4+ T cells and tumor-associated macrophages (TAMs). This infiltration, particularly of CD4+ T cells, is linked to poorer clinical outcomes, suggesting Caprin-1 may help cancer cells evade immune surveillance.
  • ULK1/STK38 Axis: The interaction of Caprin-1 with ULK1 and STK38 is central to its role in autophagy activation and subsequent tumor promotion.
  • Therapeutic Target Potential: The findings highlight Caprin-1 as a promising therapeutic target for PDAC, with potential for combination therapies to overcome immune resistance.

Key Results

  • Caprin-1 was significantly upregulated in advanced PDAC and associated with shorter overall survival.
  • Overexpression of Caprin-1 accelerated pancreatic cancer cell proliferation and tumor growth in vitro and in vivo. Conversely, Caprin-1 knockdown inhibited these processes.
  • Caprin-1 directly interacts with ULK1 and modulates its phosphorylation, leading to autophagy activation.
  • Higher levels of Caprin-1 were associated with increased infiltration of CD4+ T cells and TAMs in PDAC tissues.
  • The presence of CD4+ T cells in Caprin-1-high tumors was a significant predictor of poor prognosis.
  • In Caprin-1-high tumors, higher STK38 levels were associated with poor prognosis, while ULK1 levels did not predict outcome.

Limitations and Future Work

  • CD4+ T Cell Subtypes: While the study shows CD4+ T cell infiltration is linked to poor outcomes in Caprin-1-high tumors, further research is needed to identify specific subtypes of CD4+ T cells involved and their precise roles.
  • Autophagy's Dual Role: The paper acknowledges the complex and sometimes paradoxical roles of autophagy in cancer, suggesting further investigation into how Caprin-1-induced autophagy specifically contributes to tumorigenesis and immune evasion.
  • Mechanism of Immune Evasion: While Caprin-1 recruits immune cells, the exact mechanisms by which it facilitates immune evasion and potentially inactivates cytotoxic T cells require more detailed exploration.
  • Therapeutic Strategies: The study suggests Caprin-1 as a therapeutic target, but future work will need to focus on developing and testing specific inhibitors or combination therapies to translate these findings into clinical applications.

Summary updated

Abstract

Our findings establish causal links between the upregulated expression of Caprin-1 and autophagy activation, which may manipulate immune responses in PDAC development. Our study provides insights into considering Caprin-1 as potential therapeutic target for PDAC treatment.
BibTeX
@article{yang2023caprin,
  author = {Wenbo Yang and Hongze Chen and Guanqun Li and Tao Zhang and Yuhang Sui and Liwei Liu and Jisheng Hu and Gang Wang and Hua Chen and Yongwei Wang and Xina Li and Hongtao Tan and Rui Kong and Bei Sun and Le Li},
  title = {{Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer}},
  journal = {Journal of Translational Medicine},
  year = {2023},
  doi = {10.1186/s12967-023-04693-4},
}
Figure